Latest News
BioMed Technology Funded by TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness
2023-04-21
BioMed Technology Funded by TIMC, Alibaba Hong Kong Entrepreneurs Fund and Gobi to Realise Precision and Personalised Gut Microbiome Management for Wellness
BioMed Technology Holdings Limited (BioMed), Hong Kong's leading microbiome startup, has raised USD 2 million in its latest oversubscribed seed round from The International Medical Co. Ltd. (TIMC), Alibaba Hong Kong Entrepreneurs Fund (AEF) and Gobi Partners GBA. The new funds will allow the company to further research and develop biotech-driven solutions that help consumers get their “best-fit” microbiome health management plan for wellness enhancement as well as to realise its expansion in mainland China and Asia. BioMed’s unique, revolutionary healthcare delivery bodes well for the future of personalised care and precision medicine.
Thinking Beyond Probiotics: Personalised and Total Microbiome Support
Being a partner company of Hong Kong Science and Technology Parks Corporation, BioMed was founded by a dedicated team of medical specialists, university professors, scientific researchers and healthcare professionals, pioneering the provision of gut microbiome-based intervention for wellnessand disease prevention.
Science shows that the gut microbiome plays a critical role in the development of various common chronic diseases, including gastrointestinal diseases, neuropsychiatric disorders, cardiovascular diseases, metabolic syndromes, eczema and allergies. BioMed’s approach is to unlock the mysterious “DNA architecture” of one’s gut microbiome that may impact his/her health and offer a personalised microbiome management plan to bring the flora back into balance.
This round of funding will be used to solidify its strategic position in Hong Kong and other emerging markets – BioMed is striving to sharpen its strategic position as a total microbiome health management expert, providing personalised and total microbiome support instead of going after the conventional health supplement market.
Joseph Lun, Chairman and CEO of The International Medical Co. Ltd. said, “Unlike other companies in the pharmaceutical or health supplement space, BioMed has its own R&D team and laboratories that provide tailor-made solutions and products to consumers. Their comprehensive approach from testing to the solution is their competitive advantage over other providers. We believe BioMed and our group of companies possess the potential to further disrupt the gastrointestinal health market through collaborative research and development.”
Media reports: